Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen Challenge

Stephane Esnault, Elizabeth A. Kelly, Elizabeth A. Schwantes, Lin Ying Liu, Larissa P. DeLain, Jami A. Hauer, Yury A. Bochkov, Loren C. Denlinger, James S. Malter, Sameer K. Mathur, Nizar N. Jarjour

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: The mechanism for the contribution of eosinophils (EOS) to asthma pathophysiology is not fully understood. Genome-wide expression analysis of airway EOS by microarrays has been limited by the ability to generate high quality RNA from sufficient numbers of airway EOS. Objective: To identify, by genome-wide expression analyses, a compendium of expressed genes characteristic of airway EOS following an in vivo allergen challenge. Methods: Atopic, mild asthmatic subjects were recruited for these studies. Induced sputum was obtained before and 48h after a whole lung allergen challenge (WLAC). Individuals also received a segmental bronchoprovocation with allergen (SBP-Ag) 1 month before and after administering a single dose of mepolizumab (anti-IL-5 monoclonal antibody) to reduce airway EOS. Bronchoalveolar lavage (BAL) was performed before and 48 h after SBP-Ag. Gene expression of sputum and BAL cells was analyzed by microarrays. The results were validated by qPCR in BAL cells and purified BAL EOS. Results: A total of 299 transcripts were up-regulated by more than 2-fold in total BAL cells following SBP-Ag. Mepolizumab treatment resulted in a reduction of airway EOS by 54.5% and decreased expression of 99 of the 299 transcripts. 3 of 6 post-WLAC sputum samples showed increased expression of EOS-specific genes, along with the expression of 361 other genes. Finally, the intersection of the 3 groups of transcripts (increased in BAL post SBP-Ag (299), decreased after mepolizumab (99), and increased in sputum after WLAC (365)) was composed of 57 genes characterizing airway EOS gene expression. Conclusion: We identified 57 genes that were highly expressed by BAL EOS compared to unseparated BAL cells after in vivo allergen challenge. 41 of these genes had not been previously described in EOS and are thus potential new candidates to elucidate EOS contribution to airway biology.

Original languageEnglish (US)
Article numbere67560
JournalPLoS One
Volume8
Issue number7
DOIs
StatePublished - Jul 2 2013

Fingerprint

eosinophils
allergens
Eosinophils
Allergens
Genes
Bronchoalveolar Lavage
genes
Sputum
Microarrays
Gene expression
lungs
Lung
Interleukin-5
Genome
cells
Gene Expression
gene expression
interleukin-5
genome
Monoclonal Antibodies

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Esnault, S., Kelly, E. A., Schwantes, E. A., Liu, L. Y., DeLain, L. P., Hauer, J. A., ... Jarjour, N. N. (2013). Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen Challenge. PLoS One, 8(7), [e67560]. https://doi.org/10.1371/journal.pone.0067560

Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen Challenge. / Esnault, Stephane; Kelly, Elizabeth A.; Schwantes, Elizabeth A.; Liu, Lin Ying; DeLain, Larissa P.; Hauer, Jami A.; Bochkov, Yury A.; Denlinger, Loren C.; Malter, James S.; Mathur, Sameer K.; Jarjour, Nizar N.

In: PLoS One, Vol. 8, No. 7, e67560, 02.07.2013.

Research output: Contribution to journalArticle

Esnault, S, Kelly, EA, Schwantes, EA, Liu, LY, DeLain, LP, Hauer, JA, Bochkov, YA, Denlinger, LC, Malter, JS, Mathur, SK & Jarjour, NN 2013, 'Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen Challenge', PLoS One, vol. 8, no. 7, e67560. https://doi.org/10.1371/journal.pone.0067560
Esnault, Stephane ; Kelly, Elizabeth A. ; Schwantes, Elizabeth A. ; Liu, Lin Ying ; DeLain, Larissa P. ; Hauer, Jami A. ; Bochkov, Yury A. ; Denlinger, Loren C. ; Malter, James S. ; Mathur, Sameer K. ; Jarjour, Nizar N. / Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen Challenge. In: PLoS One. 2013 ; Vol. 8, No. 7.
@article{80d259dfe9004f0ea59ea7d7071890eb,
title = "Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen Challenge",
abstract = "Background: The mechanism for the contribution of eosinophils (EOS) to asthma pathophysiology is not fully understood. Genome-wide expression analysis of airway EOS by microarrays has been limited by the ability to generate high quality RNA from sufficient numbers of airway EOS. Objective: To identify, by genome-wide expression analyses, a compendium of expressed genes characteristic of airway EOS following an in vivo allergen challenge. Methods: Atopic, mild asthmatic subjects were recruited for these studies. Induced sputum was obtained before and 48h after a whole lung allergen challenge (WLAC). Individuals also received a segmental bronchoprovocation with allergen (SBP-Ag) 1 month before and after administering a single dose of mepolizumab (anti-IL-5 monoclonal antibody) to reduce airway EOS. Bronchoalveolar lavage (BAL) was performed before and 48 h after SBP-Ag. Gene expression of sputum and BAL cells was analyzed by microarrays. The results were validated by qPCR in BAL cells and purified BAL EOS. Results: A total of 299 transcripts were up-regulated by more than 2-fold in total BAL cells following SBP-Ag. Mepolizumab treatment resulted in a reduction of airway EOS by 54.5{\%} and decreased expression of 99 of the 299 transcripts. 3 of 6 post-WLAC sputum samples showed increased expression of EOS-specific genes, along with the expression of 361 other genes. Finally, the intersection of the 3 groups of transcripts (increased in BAL post SBP-Ag (299), decreased after mepolizumab (99), and increased in sputum after WLAC (365)) was composed of 57 genes characterizing airway EOS gene expression. Conclusion: We identified 57 genes that were highly expressed by BAL EOS compared to unseparated BAL cells after in vivo allergen challenge. 41 of these genes had not been previously described in EOS and are thus potential new candidates to elucidate EOS contribution to airway biology.",
author = "Stephane Esnault and Kelly, {Elizabeth A.} and Schwantes, {Elizabeth A.} and Liu, {Lin Ying} and DeLain, {Larissa P.} and Hauer, {Jami A.} and Bochkov, {Yury A.} and Denlinger, {Loren C.} and Malter, {James S.} and Mathur, {Sameer K.} and Jarjour, {Nizar N.}",
year = "2013",
month = "7",
day = "2",
doi = "10.1371/journal.pone.0067560",
language = "English (US)",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "7",

}

TY - JOUR

T1 - Identification of Genes Expressed by Human Airway Eosinophils after an In Vivo Allergen Challenge

AU - Esnault, Stephane

AU - Kelly, Elizabeth A.

AU - Schwantes, Elizabeth A.

AU - Liu, Lin Ying

AU - DeLain, Larissa P.

AU - Hauer, Jami A.

AU - Bochkov, Yury A.

AU - Denlinger, Loren C.

AU - Malter, James S.

AU - Mathur, Sameer K.

AU - Jarjour, Nizar N.

PY - 2013/7/2

Y1 - 2013/7/2

N2 - Background: The mechanism for the contribution of eosinophils (EOS) to asthma pathophysiology is not fully understood. Genome-wide expression analysis of airway EOS by microarrays has been limited by the ability to generate high quality RNA from sufficient numbers of airway EOS. Objective: To identify, by genome-wide expression analyses, a compendium of expressed genes characteristic of airway EOS following an in vivo allergen challenge. Methods: Atopic, mild asthmatic subjects were recruited for these studies. Induced sputum was obtained before and 48h after a whole lung allergen challenge (WLAC). Individuals also received a segmental bronchoprovocation with allergen (SBP-Ag) 1 month before and after administering a single dose of mepolizumab (anti-IL-5 monoclonal antibody) to reduce airway EOS. Bronchoalveolar lavage (BAL) was performed before and 48 h after SBP-Ag. Gene expression of sputum and BAL cells was analyzed by microarrays. The results were validated by qPCR in BAL cells and purified BAL EOS. Results: A total of 299 transcripts were up-regulated by more than 2-fold in total BAL cells following SBP-Ag. Mepolizumab treatment resulted in a reduction of airway EOS by 54.5% and decreased expression of 99 of the 299 transcripts. 3 of 6 post-WLAC sputum samples showed increased expression of EOS-specific genes, along with the expression of 361 other genes. Finally, the intersection of the 3 groups of transcripts (increased in BAL post SBP-Ag (299), decreased after mepolizumab (99), and increased in sputum after WLAC (365)) was composed of 57 genes characterizing airway EOS gene expression. Conclusion: We identified 57 genes that were highly expressed by BAL EOS compared to unseparated BAL cells after in vivo allergen challenge. 41 of these genes had not been previously described in EOS and are thus potential new candidates to elucidate EOS contribution to airway biology.

AB - Background: The mechanism for the contribution of eosinophils (EOS) to asthma pathophysiology is not fully understood. Genome-wide expression analysis of airway EOS by microarrays has been limited by the ability to generate high quality RNA from sufficient numbers of airway EOS. Objective: To identify, by genome-wide expression analyses, a compendium of expressed genes characteristic of airway EOS following an in vivo allergen challenge. Methods: Atopic, mild asthmatic subjects were recruited for these studies. Induced sputum was obtained before and 48h after a whole lung allergen challenge (WLAC). Individuals also received a segmental bronchoprovocation with allergen (SBP-Ag) 1 month before and after administering a single dose of mepolizumab (anti-IL-5 monoclonal antibody) to reduce airway EOS. Bronchoalveolar lavage (BAL) was performed before and 48 h after SBP-Ag. Gene expression of sputum and BAL cells was analyzed by microarrays. The results were validated by qPCR in BAL cells and purified BAL EOS. Results: A total of 299 transcripts were up-regulated by more than 2-fold in total BAL cells following SBP-Ag. Mepolizumab treatment resulted in a reduction of airway EOS by 54.5% and decreased expression of 99 of the 299 transcripts. 3 of 6 post-WLAC sputum samples showed increased expression of EOS-specific genes, along with the expression of 361 other genes. Finally, the intersection of the 3 groups of transcripts (increased in BAL post SBP-Ag (299), decreased after mepolizumab (99), and increased in sputum after WLAC (365)) was composed of 57 genes characterizing airway EOS gene expression. Conclusion: We identified 57 genes that were highly expressed by BAL EOS compared to unseparated BAL cells after in vivo allergen challenge. 41 of these genes had not been previously described in EOS and are thus potential new candidates to elucidate EOS contribution to airway biology.

UR - http://www.scopus.com/inward/record.url?scp=84879764799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879764799&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0067560

DO - 10.1371/journal.pone.0067560

M3 - Article

C2 - 23844029

AN - SCOPUS:84879764799

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 7

M1 - e67560

ER -